title: The United States Food and Drug Administration guidelines on ambulatory blood pressure monitoring.
abstract: The United States Food and Drug Administration (FDA) does not require the use of ambulatory blood pressure monitoring in the evaluation of antihypertensive drug efficacy. It has not so far been found useful in decision-making and there is no consensus on its use. As more ambulatory blood pressure data accumulate, however, there may be a role for this technique in helping to solve particular problems in evaluating the effects of antihypertensive drugs.
authors.affiliation: Division of CardioRenal Drug Products, Food and Drug Administration, Rockville, Maryland.
authors.forename: R
authors.initials: R
authors.lastname: Lipicky
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D015924:Blood Pressure Monitors; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D012107:Research Design; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000959:Antihypertensive Agents